At the news
? MIXEDIMPACT 6/10 8-K filed Aug 7, 2026 at 07:10 ET
Treace Medical Concepts reported Q2 2026 revenue of $45.4M (down 4% YoY but beating $43.9M consensus) and EPS of -$0.24 (beating -$0.30 consensus by 20%). The company raised full-year revenue guidance to $204M-$212M and improved Adjusted EBITDA loss guidance to $3M-$5M, while reducing year-to-date cash usage by 57%. New product adoption is accelerating, with 40% of Lapiplasty surgeons now using at least one of the three new bunion systems.
- Q2 2026 revenue $45.4M vs $47.4M YoY (-4%), beating consensus of $43.9M
- Q2 2026 GAAP EPS -$0.24 vs -$0.28 YoY, beating consensus of -$0.30
- Full-year 2026 revenue guidance raised to $204M-$212M (from $202M-$212M)
- Adjusted EBITDA loss guidance improved to $3.0M-$5.0M (from $4.0M-$6.0M)
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access